Cullinan Management, Inc. ( (CGEM) ) has released its Q3 earnings. Here is a breakdown of the information Cullinan Management, Inc. presented to its investors.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Cullinan Therapeutics, Inc., a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts, focuses on developing innovative cancer therapies. In its latest earnings report for the quarter ending September 30, 2025, Cullinan reported a significant net loss of $50.6 million, compared to a $40.6 million loss in the same period last year. The company’s operating expenses increased, driven by higher research and development costs, which rose to $41.9 million from $35.5 million in the previous year. Despite these losses, Cullinan maintains a strong cash position with $103.3 million in cash and cash equivalents, supported by investments totaling $369.3 million. The company continues to advance its pipeline, including a new licensing agreement with Genrix for velinotamig, a BCMAxCD3 bispecific T cell engager. Looking ahead, Cullinan remains focused on its research and development efforts, with sufficient financial resources to support its operations over the next twelve months.